Search Results
Aug 06, 2026, 09:00 ET Emerson Acquires Glue Inc. to Accelerate AI-Driven Test & Measurement Innovation
/PRNewswire/ -- Global automation leader Emerson (NYSE: EMR) today announced it has acquired Glue Inc., an innovator in advancing intelligent validation and test through its AI-enabled software product Glue Studio. Glue Studio features specialized AI-centric capabilities for test generation and planning. The
More news about: Emerson
Aug 04, 2026, 12:56 ET ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Aug 04, 2026, 10:00 ET Convex Raises $57M Series B Led by Insight Partners to Scale the Reliable Backend for the AI Era
with you and your agents. Convex comes with a database, functions, workflow, sync, search, file storage and more included; all in TypeScript with zero glue code. ACID transactions, end-to-end type safety, and realtime subscriptions are default. Founded by early Dropbox infrastructure engineers, Convex is
More news about: Convex
Jul 31, 2026, 22:00 ET Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company's ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk
More news about: Kahn Swick & Foti, LLC
Jul 31, 2026, 14:41 ET ERAS AUGUST 10, 2026 DEADLINE: Erasca, Inc. Investors Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 30, 2026, 06:59 ET Road Marking Materials Market worth $9.38 billion by 2031 - Exclusive Report by MarketsandMarkets™
Luxury Vinyl Tiles Market by Type (Rigid, Flexible), Product Type (Click LVT, Glue-down LVT), Distribution Channel (Retail Stores, Online Retail), End-use Sector (Residential, Commercial), & Region - Global Forecast to 2030About
More news about: MarketsandMarkets
Jul 29, 2026, 13:26 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - Hagens Berman
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 29, 2026, 10:09 ET Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS
RMC-6236At the Annual J.P. Morgan Healthcare Conference, Erasca's management presented ERAS-0015 as a "potential best-in-class pan-RAS molecular glue" and drew detailed comparisons to Revolution Medicines' RMC-6236. The lawsuit contends that these comparisons were improper from the outset, placing
More news about: Levi & Korsinsky, LLP
Jul 28, 2026, 10:10 ET ERAS AUGUST 10, 2026 DEADLINE: Erasca, Inc. Investors Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 27, 2026, 09:30 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 24, 2026, 22:00 ET Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company's ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk
More news about: ClaimsFiler
Jul 24, 2026, 09:00 ET ERAS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors.The Erasca class action lawsuit alleges that defendants throughout
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 08:00 ET ERAS Investor Alert: HBSS Investigating Pending Claims Against Erasca (ERAS) in Securities Class Action Arising from Patent Litigation and Patient Safety Risks
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
collaboration with Johnson & Johnson to advance the discovery of important molecular glue targets in oncology. The collaboration aims to advance next-generation molecular glue degraders by applying TRIANA's proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 22, 2026, 12:26 ET NASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Action
focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. The Company's lead product candidate, ERAS-0015, is a pan-RAS molecular glue in development for the treatment of patients with RAS-mutated solid tumors.According to the complaint, throughout the Class Period, Defendants
More news about: Berger Montague
Jul 22, 2026, 10:07 ET ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
Investors Were Not ToldFor more than 15 months, Erasca's management presented ERAS-0015 as a "potential best-in-class pan-RAS molecular glue" with superior preclinical properties to RevMed's RMC-6236. Across multiple J.P. Morgan Healthcare Conference presentations, SEC filings, and investor
More news about: Levi & Korsinsky, LLP
Jul 22, 2026, 06:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 16:26 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 10:43 ET Meijer Offering 50+ School Supplies for Under $1 in One-Stop Back-To-School Shopping Experience for Families
commonly found on back-to-school supply lists. Examples include: Meijer Washable Glue Stick 2-pack: $0.25Meijer Crayons: $0.25Meijer Washable School Glue: $0.25Meijer Washable Markers: $0.74Meijer Colored Pencils: $0.50Popular
More news about: Meijer
Jul 21, 2026, 06:00 ET ZELLERFELD GIVES FOOTWEAR ITS SPOTIFY MOMENT
product creation, custom fit and distributed 3D-printed production, turning shoes from digital files into physical products without moulds, stitching, glue or traditional assembly. Zellerfeld has proven the model across sport, fashion, design and culture: products designed digitally, fitted personally and
More news about: Zellerfeld
Jul 17, 2026, 22:00 ET Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company's ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk
More news about: Kahn Swick & Foti, LLC
Jul 17, 2026, 08:03 ET BRIJ Medical Launches BRIJ-SEAL™, Expanding Its Incision Management Portfolio with an Advanced Wound Sealant
in the Industry: Safeguards the surgical site and reduces risk of surgical site infection.Hypoallergenic: No glue. No cyanoacrylates. Just the same, trusted, hypoallergenic adhesive as Brijjit, which had no allergic reactions in 6 clinical trials.Easy
More news about: BRIJ Medical
Jul 16, 2026, 10:07 ET ERAS DEADLINE: SueWallSt Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
deadline is August 10, 2026.How Alleged Improper Benchmarking Shaped Erasca's Investment ThesisThe pan-RAS molecular glue market represents a high-stakes frontier in precision oncology, with RAS mutations driving nearly one-fourth of all solid tumors worldwide. Erasca built
More news about: SueWallSt.com
Jul 16, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:Improper Preclinical Comparisons: Allegedly
More news about: Hagens Berman Sobol Shapiro LLP